1-5 of 5
Patricia LoRusso
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)

Edward Maldonado, W. Kimryn Rathmell, Geoffrey I. Shapiro, Naoko Takebe, Jordi Rodon, Devalingam Mahalingam, Nikolaos A. Trikalinos, Arash R. Kalebasty, Mamta Parikh, Scott A. Boerner, Celene Balido, Gregor Krings, Timothy F. Burns, Emily K. Bergsland, Pamela N. Munster, Alan Ashworth, Patricia LoRusso, Rahul R. Aggarwal
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (7): 1793–1801.
https://doi.org/10.1158/2767-9764.CRC-24-0213
Published: 23 July 2024
View article titled, A Phase II Trial of the WEE1 Inhibitor Adavosertib in <em>SETD2</em><em>-</em>Altered Advanced Solid Tumor Malignancies (NCI 10170)
Open the PDF for A Phase II Trial of the WEE1 Inhibitor Adavosertib in <em>SETD2</em><em>-</em>Altered Advanced Solid Tumor Malignancies (NCI 10170) in another window
Includes: Supplementary data
Journal Articles

A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors

Michael A. Carducci, Ding Wang, Christina Habermehl, Matthias Bödding, Felix Rohdich, Floriane Lignet, Klaus Duecker, Oleksandr Karpenko, Linda Pudelko, Claude Gimmi, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1638–1647.
https://doi.org/10.1158/2767-9764.CRC-23-0048
Published: 24 August 2023
View article titled, A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors
Open the PDF for A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors in another window
Journal Articles

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Michael Cecchini, Janie Y. Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong, Yong Kong, Hongyu Zhao, Jassim DiPalermo, Lesley Devine, Stacey M. Stein, Jeremy Kortmansky, Kimberly L. Johung, Ranjit S. Bindra, Patricia LoRusso, Kurt A. Schalper
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1132–1139.
https://doi.org/10.1158/2767-9764.CRC-23-0045
Published: 28 June 2023
View article titled, Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Open the PDF for Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A. Boerner, Diane E. Durecki, Joseph P. Eder, Kurt A. Schalper, Alice P. Chen, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (6): 1113–1117.
https://doi.org/10.1158/2767-9764.CRC-22-0485
Published: 26 June 2023
View article titled, NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
Open the PDF for NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (2): 192–201.
https://doi.org/10.1158/2767-9764.CRC-22-0436
Published: 02 February 2023
View article titled, Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <em>IDH1-</em> and <em>IDH2</em>-mutant Glioma
Open the PDF for Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <em>IDH1-</em> and <em>IDH2</em>-mutant Glioma in another window
Includes: Supplementary data